Forgetfulness to take antihypertensive medications and poor blood pressure control in older adults with type 2 diabetes and hypertension in Vietnam

preprint OA: closed
📄 Open PDF Full text JSON View at publisher

Abstract

Background Poor adherence to antihypertensive medications is very common in older adults. One of the leading causes of poor adherence is forgetfulness, which can be particularly challenging to manage because it is often unintentional. A better understanding of the impact of forgetfulness can help in developing targeted interventions to improve BP control. Aim This study aimed to (1) examine the prevalence of forgetfulness to take antihypertensive medications and its associated factors in older adults with type 2 diabetes and hypertension in Vietnam, and (2) investigate the relationship between forgetfulness to take antihypertensive medications and poor blood pressure (BP) control in this population. Methods This observational study was conducted at the outpatient clinics of two major hospitals in Vietnam from June 2023 to June 2024. Forgetfulness was assessed using the question: “Do you sometimes forget to take your prescribed antihypertensive medications?”, with the answer of “Yes” or “No”. Poor BP control was defined as mean systolic BP ≥140 mmHg or a mean diastolic BP ≥90 mmHg. Logistic regression analysis was conducted to examine the associated factors for forgetfulness and the relationship between forgetfulness and poor BP control. Results are presented as odds ratios (ORs) and 95% confidence intervals (CIs). Results There were 448 participants. They had a mean age of 73.5 years (SD 7.2), 32.1% were female. The prevalence of forgetfulness to take antihypertensives was 29.5%, highest among participants in the first 5 years of hypertension (43.8%), followed by those with >15 years (28.0%), 11-15 years (25.2%), and 6-10 years (23.9%) (p=0.009). Logistic regression analysis revealed that hypertension duration and disability in activities of daily living were significantly associated with forgetfulness. Forgetfulness increased the odds of poor BP control, with an adjusted OR of 1.64 (95%CI 1.03 -2.56). Conclusion In this study, there was a high prevalence of forgetfulness to take antihypertensive medications, and forgetfulness was associated with increased odds of poor BP control. These findings suggest the need for future studies focusing on interventions on forgetfulness to improve medication adherence for this population. Further support is particularly needed for older adults with disability and for those newly diagnosed with hypertension.
Full text 4,089 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Abstract

Background Poor adherence to antihypertensive medications is very common in older adults. One of the leading causes of poor adherence is forgetfulness, which can be particularly challenging to manage because it is often unintentional. A better understanding of the impact of forgetfulness can help in developing targeted interventions to improve BP control. Aim This study aimed to (1) examine the prevalence of forgetfulness to take antihypertensive medications and its associated factors in older adults with type 2 diabetes and hypertension in Vietnam, and (2) investigate the relationship between forgetfulness to take antihypertensive medications and poor blood pressure (BP) control in this population.

Methods

This observational study was conducted at the outpatient clinics of two major hospitals in Vietnam from June 2023 to June 2024. Forgetfulness was assessed using the question: “Do you sometimes forget to take your prescribed antihypertensive medications?”, with the answer of “Yes” or “No”. Poor BP control was defined as mean systolic BP ≥140 mmHg or a mean diastolic BP ≥90 mmHg. Logistic regression analysis was conducted to examine the associated factors for forgetfulness and the relationship between forgetfulness and poor BP control. Results are presented as odds ratios (ORs) and 95% confidence intervals (CIs).

Results

There were 448 participants. They had a mean age of 73.5 years (SD 7.2), 32.1% were female. The prevalence of forgetfulness to take antihypertensives was 29.5%, highest among participants in the first 5 years of hypertension (43.8%), followed by those with >15 years (28.0%), 11-15 years (25.2%), and 6-10 years (23.9%) (p=0.009). Logistic regression analysis revealed that hypertension duration and disability in activities of daily living were significantly associated with forgetfulness. Forgetfulness increased the odds of poor BP control, with an adjusted OR of 1.64 (95%CI 1.03 -2.56).

Conclusion

In this study, there was a high prevalence of forgetfulness to take antihypertensive medications, and forgetfulness was associated with increased odds of poor BP control. These findings suggest the need for future studies focusing on interventions on forgetfulness to improve medication adherence for this population. Further support is particularly needed for older adults with disability and for those newly diagnosed with hypertension. Competing Interest Statement The authors have declared no competing interest. Funding Statement This study did not receive any funding Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics Committees of the University of Medicine and Pharmacy at Ho Chi Minh City (Reference Number 627/HDDD-DHYD, date 26/06/2023) provided ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00